| 1.34 -0.39 (-22.54%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.41 | 1-year : | 3.1 |
| Resists | First : | 2.07 | Second : | 2.66 |
| Pivot price | 1.34  |
|||
| Supports | First : | 1.12 | Second : | 0.93 |
| MAs | MA(5) : | 1.45 |
MA(20) : | 1.32 |
| MA(100) : | 1.64 |
MA(250) : | 1.49 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.4 |
D(3) : | 59.3 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 3.78 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIVI ] has closed above bottom band by 48.8%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.58 - 1.59 | 1.59 - 1.6 |
| Low: | 1.15 - 1.16 | 1.16 - 1.17 |
| Close: | 1.33 - 1.34 | 1.34 - 1.35 |
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Wed, 04 Nov 2026
One investor agreed to buy 2.96 million BioVie shares, with rights to buy up to 2.96 million more. - Stock Titan
Wed, 04 Nov 2026
A $6.46M stock-sale ceiling is cut as BioVie (BIVI) reduces its offering. - Stock Titan
Wed, 04 Nov 2026
BioVie to raise $4.74 million in registered direct offering - Proactive financial news
Tue, 03 Nov 2026
BioVie Inc. (BIVI) stock price, news, quote and history - Yahoo Finance UK
Mon, 02 Nov 2026
BioVie Inc. (BIVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 02 Nov 2026
BioVie to present new Long COVID biomarker data at Nice conference - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 22.1 (%) |
| Shares Short | 831 (K) |
| Shares Short P.Month | 885 (K) |
| EPS | -3.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -79.1 % |
| Return on Equity (ttm) | -150.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.44 |
| PEG Ratio | 0 |
| Price to Book value | 0.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|